RA Capital Management L.P. Makes New Investment in Septerna, Inc. (NASDAQ:SEPN)

RA Capital Management L.P. bought a new stake in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,995,858 shares of the company's stock, valued at approximately $160,205,000. Septerna comprises approximately 2.1% of RA Capital Management L.P.'s investment portfolio, making the stock its 12th biggest holding. RA Capital Management L.P. owned approximately 15.76% of Septerna as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. TRV GP V LLC acquired a new position in shares of Septerna during the fourth quarter worth approximately $142,337,000. TRV GP VI LLC acquired a new stake in Septerna in the fourth quarter worth about $72,191,000. Samsara BioCapital LLC acquired a new position in Septerna during the 4th quarter valued at about $63,399,000. Avoro Capital Advisors LLC acquired a new stake in shares of Septerna in the 4th quarter worth approximately $25,419,000. Finally, Vanguard Group Inc. acquired a new position in shares of Septerna during the fourth quarter valued at approximately $22,557,000.

Insider Activity at Septerna

In related news, Director Alan Ezekowitz bought 41,355 shares of Septerna stock in a transaction that occurred on Thursday, March 6th. The stock was acquired at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the purchase, the director now owns 104,101 shares in the company, valued at approximately $624,606. This represents a 65.91 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Gil M. Labrucherie bought 6,282 shares of Septerna stock in a transaction that occurred on Tuesday, February 25th. The stock was purchased at an average cost of $5.59 per share, with a total value of $35,116.38. Following the completion of the transaction, the chief financial officer now owns 36,282 shares of the company's stock, valued at $202,816.38. This trade represents a 20.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 74,346 shares of company stock valued at $439,670.

Septerna Stock Down 8.4 %

Shares of Septerna stock traded down $0.61 on Tuesday, reaching $6.56. 95,016 shares of the company were exchanged, compared to its average volume of 415,629. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The business has a fifty day simple moving average of $6.12.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.13 million. Analysts expect that Septerna, Inc. will post -7.11 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SEPN. Wells Fargo & Company lowered their price target on Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Friday, March 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.